LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of $40.00 per share. The offering is expected to close on or about October 25, 2016, subject to customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to 562,500 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being sold by Puma Biotechnology.

Citigroup and J.P. Morgan are acting as lead book-running managers, Credit Suisse is acting as joint book-running manager and BofA Merrill Lynch is acting as lead manager for the offering. Stifel is acting as co-manager for the offering.

The offering is being made pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on January 20, 2015. A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at (800) 831-9146; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by phone at (866) 803-9204; or Credit Suisse, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037, or by email at [email protected].

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161019006623/en/